EP2495252A3 - Formes solubles de glycoproteine G des virus hendra et nipah - Google Patents

Formes solubles de glycoproteine G des virus hendra et nipah Download PDF

Info

Publication number: EP2495252A3
Authority: EP; European Patent Office
Prior art keywords: hendra; glycoprotein; soluble forms; nipah virus; nipah
Prior art date: 2004-07-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP12157071.7A

Other languages

German (de)

English (en)

Other versions

EP2495252B1 (fr

EP2495252A2 (fr

Inventor

Christopher C Broder

Katharine N Bossart

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Henry M Jackson Foundation for Advancedment of Military Medicine Inc

Original Assignee

Henry M Jackson Foundation for Advancedment of Military Medicine Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-09

Filing date

2005-07-07

Publication date

2013-05-01

2005-07-07 Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc

2005-07-07 Priority to EP18160722.7A priority Critical patent/EP3381930B1/fr

2012-09-05 Publication of EP2495252A2 publication Critical patent/EP2495252A2/fr

2013-05-01 Publication of EP2495252A3 publication Critical patent/EP2495252A3/fr

2018-04-18 Application granted granted Critical

2018-04-18 Publication of EP2495252B1 publication Critical patent/EP2495252B1/fr

2025-07-07 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/065—Poxviridae, e.g. avipoxvirus
- C07K14/07—Vaccinia virus; Variola virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18271—Demonstrated in vivo effect

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Cell Biology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Pulmonology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
General Engineering & Computer Science (AREA)
Oncology (AREA)

EP12157071.7A 2004-07-09 2005-07-07 Formes solubles de glycoproteine G des virus hendra et nipah Expired - Lifetime EP2495252B1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP18160722.7A EP3381930B1 (fr)	2004-07-09	2005-07-07	Formes solubles de glycoproteine g des virus hendra et nipah

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US58684304P	2004-07-09	2004-07-09
EP05857509.3A EP1789593B1 (fr)	2004-07-09	2005-07-07	Formes solubles de glycoproteine g des virus hendra

Related Parent Applications (3)

Application Number	Title	Priority Date	Filing Date
EP05857509.3A Division EP1789593B1 (fr)	2004-07-09	2005-07-07	Formes solubles de glycoproteine g des virus hendra
EP05857509.3A Division-Into EP1789593B1 (fr)	2004-07-09	2005-07-07	Formes solubles de glycoproteine g des virus hendra
EP05857509.3 Division		2005-07-07

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
EP18160722.7A Division EP3381930B1 (fr)	2004-07-09	2005-07-07	Formes solubles de glycoproteine g des virus hendra et nipah
EP18160722.7A Division-Into EP3381930B1 (fr)	2004-07-09	2005-07-07	Formes solubles de glycoproteine g des virus hendra et nipah

Publications (3)

Publication Number	Publication Date
EP2495252A2 EP2495252A2 (fr)	2012-09-05
EP2495252A3 true EP2495252A3 (fr)	2013-05-01
EP2495252B1 EP2495252B1 (fr)	2018-04-18

Family

ID=36793510

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EP05857509.3A Expired - Lifetime EP1789593B1 (fr)	2004-07-09	2005-07-07	Formes solubles de glycoproteine g des virus hendra
EP12157071.7A Expired - Lifetime EP2495252B1 (fr)	2004-07-09	2005-07-07	Formes solubles de glycoproteine G des virus hendra et nipah
EP18160722.7A Expired - Lifetime EP3381930B1 (fr)	2004-07-09	2005-07-07	Formes solubles de glycoproteine g des virus hendra et nipah

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP05857509.3A Expired - Lifetime EP1789593B1 (fr)	2004-07-09	2005-07-07	Formes solubles de glycoproteine g des virus hendra

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP18160722.7A Expired - Lifetime EP3381930B1 (fr)	2004-07-09	2005-07-07	Formes solubles de glycoproteine g des virus hendra et nipah

Country Status (7)

Country	Link
US (7)	US8865171B2 (fr)
EP (3)	EP1789593B1 (fr)
AU (2)	AU2005327194B2 (fr)
ES (2)	ES2673972T3 (fr)
PT (2)	PT1789593T (fr)
TR (1)	TR201808440T4 (fr)
WO (1)	WO2006085979A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1789593T (pt)	2004-07-09	2017-04-24	Henry M Jackson Found Advancement Military Medicine Inc	Formas solúveis de glicoproteína g de vírus hendra
KR20200040899A (ko) *	2011-05-13	2020-04-20	조에티스 서비시즈 엘엘씨	헨드라 및 니파 바이러스 ｇ 당단백질 면역원성 조성물
NZ618125A (en)	2011-05-27	2016-03-31	Merial Ltd	Genetic vaccines against hendra virus and nipah virus
CN109078179A (zh) *	2013-09-05	2018-12-25	硕腾服务有限责任公司	Hendra和Nipah病毒G糖蛋白免疫原性组合物
KR20160077214A (ko) *	2013-12-16	2016-07-01	조에티스 서비시즈 엘엘씨	헨드라 및 니파 바이러스 ｇ 당단백질 면역원성 조성물
CN108624602B (zh) *	2017-03-24	2020-10-16	华中农业大学	一株具有阻断活性的抗尼帕病毒g蛋白的单克隆抗体及其应用
KR20200090836A (ko)	2017-12-20	2020-07-29	조에티스 서비시즈 엘엘씨	Hendra 및 Nipah 바이러스 감염을 대비한 백신
WO2020028902A1 (fr)	2018-08-03	2020-02-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Immunogènes du virus nipah et leur utilisation
CN116515865B (zh) *	2023-06-19	2025-11-14	中国人民解放军军事科学院军事医学研究院	一种以人复制缺陷腺病毒为载体的尼帕病毒病疫苗
CN118812706B (zh) *	2024-08-21	2025-09-12	武汉大学	靶向尼帕病毒g蛋白的保护性单克隆抗体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007005244A1 (fr) *	2005-07-05	2007-01-11	The Regents Of The University Of California	Recepteur de l'henipavirus et ses utilisations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4777127A (en)	1985-09-30	1988-10-11	Labsystems Oy	Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5219740A (en)	1987-02-13	1993-06-15	Fred Hutchinson Cancer Research Center	Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en)	1988-05-30	1995-06-06	Depotech Corporation	Heterovesicular liposomes
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
EP0454781B1 (fr)	1989-01-23	1998-12-16	Chiron Corporation	Cellules de recombinaison pour des therapies d'infections et de troubles hyperproliferatifs et la preparation de ces cellules
US6673776B1 (en)	1989-03-21	2004-01-06	Vical Incorporated	Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
DE69034168T3 (de)	1989-03-21	2013-04-11	Vical, Inc.	Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
EP1645635A3 (fr)	1989-08-18	2010-07-07	Oxford Biomedica (UK) Limited	Retrovirus recombinants défectifs pour la réplication exprimant un palliatif
US5585362A (en)	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
NZ237464A (en)	1990-03-21	1995-02-24	Depotech Corp	Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
DE69233013T2 (de)	1991-08-20	2004-03-04	The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer	Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
AU669124B2 (en)	1991-09-18	1996-05-30	Kyowa Hakko Kirin Co., Ltd.	Process for producing humanized chimera antibody
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
WO1993010218A1 (fr)	1991-11-14	1993-05-27	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Vecteurs comprenant des genes etrangers et des marqueurs selectifs negatifs
GB9125623D0 (en)	1991-12-02	1992-01-29	Dynal As	Cell modification
FR2688514A1 (fr)	1992-03-16	1993-09-17	Centre Nat Rech Scient	Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
JPH07507689A (ja)	1992-06-08	1995-08-31	ザリージェンツオブザユニバーシティオブカリフォルニア	特定組織のターゲティング方法及び組成物
JPH09507741A (ja)	1992-06-10	1997-08-12	アメリカ合衆国	ヒト血清による不活性化に耐性のあるベクター粒子
GB2269175A (en)	1992-07-31	1994-02-02	Imperial College	Retroviral vectors
CA2592997A1 (fr)	1992-12-03	1994-06-09	Genzyme Corporation	Vecteurs pseudo-adenoviraux
AU6818094A (en)	1993-04-22	1994-11-08	Depotech Corporation	Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
JP3532566B2 (ja)	1993-06-24	2004-05-31	エル．グラハム，フランク	遺伝子治療のためのアデノウイルスベクター
EP0694070B1 (fr)	1993-09-15	2002-04-10	Chiron Corporation	Vecteurs composes d'alphavirus recombinants
US6015686A (en)	1993-09-15	2000-01-18	Chiron Viagene, Inc.	Eukaryotic layered vector initiation systems
JP3875990B2 (ja)	1993-10-25	2007-01-31	カンジ，インコーポレイテッド	組換えアデノウイルスベクターおよび使用方法
NZ276305A (en)	1993-11-16	1997-10-24	Depotech Corp	Controlled release vesicle compositions
US6436908B1 (en)	1995-05-30	2002-08-20	Duke University	Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
WO1995030763A2 (fr)	1994-05-09	1995-11-16	Chiron Viagene, Inc.	Vecteurs retroviraux a taux de recombinaison reduit
WO1996017072A2 (fr)	1994-11-30	1996-06-06	Chiron Viagene, Inc.	Vecteurs d'alphavirus de recombinaison
US6265150B1 (en)	1995-06-07	2001-07-24	Becton Dickinson & Company	Phage antibodies
AU2998597A (en)	1996-05-06	1997-11-26	Chiron Corporation	Crossless retroviral vectors
AU9692198A (en)	1997-10-10	1999-05-03	Kevin J. Donahue	Gene delivery compositions and methods
AU2004274717A1 (en) *	2003-09-22	2005-03-31	Inserm (Institut National De La Sante Et De La Recherche Medicale)	A method for detecting Nipah virus and method for providing immunoprotection against henipaviruses
PT1789593T (pt) *	2004-07-09	2017-04-24	Henry M Jackson Found Advancement Military Medicine Inc	Formas solúveis de glicoproteína g de vírus hendra
AU2005333155B2 (en) *	2005-03-14	2011-11-17	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies against Hendra and Nipah viruses

2005
- 2005-07-07 PT PT58575093T patent/PT1789593T/pt unknown
- 2005-07-07 ES ES12157071.7T patent/ES2673972T3/es not_active Expired - Lifetime
- 2005-07-07 US US11/629,682 patent/US8865171B2/en active Active
- 2005-07-07 EP EP05857509.3A patent/EP1789593B1/fr not_active Expired - Lifetime
- 2005-07-07 PT PT121570717T patent/PT2495252T/pt unknown
- 2005-07-07 EP EP12157071.7A patent/EP2495252B1/fr not_active Expired - Lifetime
- 2005-07-07 AU AU2005327194A patent/AU2005327194B2/en not_active Expired
- 2005-07-07 EP EP18160722.7A patent/EP3381930B1/fr not_active Expired - Lifetime
- 2005-07-07 WO PCT/US2005/024022 patent/WO2006085979A2/fr not_active Ceased
- 2005-07-07 ES ES05857509.3T patent/ES2622394T3/es not_active Expired - Lifetime
- 2005-07-07 TR TR2018/08440T patent/TR201808440T4/tr unknown
2010
- 2010-11-11 AU AU2010241382A patent/AU2010241382B2/en not_active Expired
2012
- 2012-06-22 US US13/530,866 patent/US9056902B2/en not_active Expired - Lifetime
- 2012-06-22 US US13/530,922 patent/US9045532B2/en not_active Expired - Lifetime
2015
- 2015-04-30 US US14/701,006 patent/US9533038B2/en not_active Expired - Lifetime
2016
- 2016-12-30 US US15/395,418 patent/US10053495B2/en not_active Expired - Lifetime
2018
- 2018-07-25 US US16/044,985 patent/US20190031719A1/en not_active Abandoned
2021
- 2021-01-29 US US17/161,720 patent/US20210230230A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007005244A1 (fr) *	2005-07-05	2007-01-11	The Regents Of The University Of California	Recepteur de l'henipavirus et ses utilisations

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BOSSART K N ET AL: "Functional expression and membrane fusion tropism of the envelope glycoproteins of Hendra virus", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 290, 10 November 2001 (2001-11-10), pages 121 - 135, XP002970804, ISSN: 0042-6822 *
BOSSART K N ET AL: "Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 79, no. 11, 1 June 2005 (2005-06-01), pages 6690 - 6702, XP002406103, ISSN: 0022-538X *
BRODER CC: "A soluble Hendra virus attachment envelope glycoprotein blocks fusion", LECTURE, 2004, 4th FREDERICK WORKSHOP ON THE CELL BIOLOGY OF VIRAL ENTRY; FREDERICK, MARYLAND, USA; 2-5 MAY 2004; *
ESHAGHI M ET AL: "Purification of the extra-cellular domain of Nipah virus glycoprotein produced in Escherichia coli and possible application in diagnosis", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 116, no. 3, 5 January 2005 (2005-01-05), pages 221 - 226, XP004737494, ISSN: 0168-1656, DOI: 10.1016/J.JBIOTEC.2004.10.020 *
HARCOURT B H ET AL: "Molecular Characterization of Nipah Virus, a Newly Emergent Paramyxovirus", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 271, no. 2, 5 June 2000 (2000-06-05), pages 334 - 349, XP004436009, ISSN: 0042-6822, DOI: 10.1006/VIRO.2000.0340 *
NEGRETE O A ET AL: "EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 436, no. 7049, 6 July 2005 (2005-07-06), pages 401 - 405, XP002406101, ISSN: 0028-0836 *
PARKS G D ET AL: "Folding and oligomerization properties of a soluble and secreted form of the paramyxovirus hemagglutinin-neuraminidase glycoprotein", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 178, no. 2, 1 October 1990 (1990-10-01), pages 498 - 508, XP023289994, ISSN: 0042-6822, [retrieved on 19901001], DOI: 10.1016/0042-6822(90)90347-T *
TAN W S ET AL: "Solubility, immunogenicity and physical properties of the nucleocapsid protein of Nipah virus produced inEscherichia coli", JOURNAL OF MEDICAL VIROLOGY, vol. 73, no. 1, 1 May 2004 (2004-05-01), pages 105 - 112, XP055057712, ISSN: 0146-6615, DOI: 10.1002/jmv.20052 *
XIAO X ET AL: "Cell biology of virus entry: a review of the 4th International Frederick Meeting", MOLECULAR MEMBRANE BIOLOGY, TAYLOR AND FRANCIS, GB, vol. 21, no. 5, 1 September 2004 (2004-09-01), pages 281 - 287, XP009125132, ISSN: 0968-7688 *

Also Published As

Publication number	Publication date
ES2673972T3 (es)	2018-06-26
EP3381930A1 (fr)	2018-10-03
US20150306208A1 (en)	2015-10-29
US20170174728A1 (en)	2017-06-22
US9056902B2 (en)	2015-06-16
EP3381930B1 (fr)	2025-04-16
PT2495252T (pt)	2018-06-22
US20130171132A1 (en)	2013-07-04
US20130171131A1 (en)	2013-07-04
EP2495252B1 (fr)	2018-04-18
WO2006085979A3 (fr)	2009-04-09
WO2006085979A2 (fr)	2006-08-17
US20210230230A1 (en)	2021-07-29
PT1789593T (pt)	2017-04-24
AU2010241382A1 (en)	2010-12-02
AU2005327194B2 (en)	2010-09-09
EP1789593A2 (fr)	2007-05-30
US10053495B2 (en)	2018-08-21
AU2010241382B2 (en)	2012-10-11
US8865171B2 (en)	2014-10-21
EP1789593B1 (fr)	2017-03-15
EP2495252A2 (fr)	2012-09-05
US20090041772A1 (en)	2009-02-12
US9533038B2 (en)	2017-01-03
TR201808440T4 (tr)	2018-07-23
AU2005327194A1 (en)	2006-08-17
US9045532B2 (en)	2015-06-02
EP1789593A4 (fr)	2009-12-23
WO2006085979A9 (fr)	2009-08-13
ES2622394T3 (es)	2017-07-06
US20190031719A1 (en)	2019-01-31

Publication	Publication Date	Title
EP3266464A3 (fr)	2018-03-14	Thérapeutique à base de levure pour infection chronique par l'hépatite b
EA201070794A1 (ru)	2011-02-28	Рекомбинантные антигены rsv
EA201270063A1 (ru)	2012-07-30	Рекомбинантные антигены pcb
UA103881C2 (ru)	2013-12-10	Профилактика или терапевтическое лечение инфекции, вызванной вирусом иммунодефицита человека
WO2006034292A3 (fr)	2009-04-16	Anticorps dirige contre le virus respiratoire syncytial et procedes de production de vaccins associes
MX2012001882A (es)	2012-04-11	Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
EP2426142A3 (fr)	2012-06-13	Souches de virus de vaccin modifiées pour une utilisation pour le diagnostic et procédé thérapeutique
EA201170353A1 (ru)	2011-12-30	Антитела против гепатита с и их применение
EA200970586A1 (ru)	2009-12-30	Антитела к цитомегаловирусу человека (hcmv)
WO2010047830A3 (fr)	2010-07-01	Agent permettant le traitement du virus de l'hépatite c
WO2006015035A8 (fr)	2006-03-09	Composés utiles pour l'infection par hpv
WO2007021672A3 (fr)	2007-11-22	Vaccination contre l'infection par le virus de la dengue
WO2009152147A3 (fr)	2010-04-15	Compositions et procédés de traitement et de vaccination contre le virus de la dengue (vd)
WO2007057763A3 (fr)	2008-07-17	Oxyde nitrique utilisé comme agent antiviral, vaccin et adjuvant de vaccin
WO2007041487A3 (fr)	2007-07-26	Peptides inhibiteurs d'infections virales
WO2008017826A3 (fr)	2008-10-02	Protéines immunogéniques et leurs utilisations
EA201000051A1 (ru)	2010-08-30	Противовирусные соединения, композиции и способы использования
WO2007150008A3 (fr)	2008-12-11	Polypeptides issus du virus de la peste porcine africaine utilisés en tant que vaccins à usage préventif et thérapeutique
EP2495252A3 (fr)	2013-05-01	Formes solubles de glycoproteine G des virus hendra et nipah
WO2008124176A3 (fr)	2009-03-19	Formes solubles et ancrées sur membrane de protéines de sous-unité du virus lassa
WO2005028496A3 (fr)	2005-10-06	Vaccin pour le traitement et la prevention de l'infection provoquee par le virus de l'herpes simplex
EA201170484A1 (ru)	2012-03-30	Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
WO2006110831A3 (fr)	2009-06-04	Methode pour induire des anticorps neutralisant le virus de l'immunodeficience humaine
WO2010041241A3 (fr)	2010-12-16	Peptides dérivés de l'intégrase du vih-1 et compositions
WO2008064072A3 (fr)	2008-10-16	Anticorps anti-tsg101 et leurs utilisations pour le traitement des infections virales

Legal Events

Date	Code	Title	Description
2012-09-04	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2012-09-05	AC	Divisional application: reference to earlier application	Ref document number: 1789593 Country of ref document: EP Kind code of ref document: P
2012-09-05	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
2013-03-28	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602005053856 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C07K0014115000 Ipc: A61K0039000000
2013-03-29	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2013-04-19	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1172355 Country of ref document: HK
2013-05-01	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
2013-05-01	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/00 20060101ALI20130328BHEP Ipc: A61K 39/00 20060101AFI20130328BHEP
2013-12-11	17P	Request for examination filed	Effective date: 20131101
2013-12-11	RBV	Designated contracting states (corrected)	Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
2014-02-19	17Q	First examination report despatched	Effective date: 20140120
2017-11-26	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2017-11-26	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2017-12-27	INTG	Intention to grant announced	Effective date: 20171127
2018-03-06	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2018-03-16	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2018-03-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2018-04-11	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMEN
2018-04-11	RIN1	Information on inventor provided before grant (corrected)	Inventor name: BOSSART, KATHARINE, N Inventor name: BRODER, CHRISTOPHER, C
2018-04-18	AC	Divisional application: reference to earlier application	Ref document number: 1789593 Country of ref document: EP Kind code of ref document: P
2018-04-18	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
2018-04-18	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2018-04-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2018-05-09	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602005053856 Country of ref document: DE
2018-05-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 989730 Country of ref document: AT Kind code of ref document: T Effective date: 20180515
2018-05-16	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2018-06-22	REG	Reference to a national code	Ref country code: PT Ref legal event code: SC4A Ref document number: 2495252 Country of ref document: PT Date of ref document: 20180622 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20180618
2018-06-26	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2673972 Country of ref document: ES Kind code of ref document: T3 Effective date: 20180626
2018-07-11	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2018-07-13	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: MICHELI AND CIE SA, CH
2018-07-26	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14
2018-09-10	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2018-10-12	REG	Reference to a national code	Ref country code: HK Ref legal event code: GR Ref document number: 1172355 Country of ref document: HK
2018-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180718 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418
2018-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418
2018-12-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 989730 Country of ref document: AT Kind code of ref document: T Effective date: 20180418
2019-01-21	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602005053856 Country of ref document: DE
2019-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418
2019-02-08	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20180401989 Country of ref document: GR Effective date: 20190125
2019-02-22	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2019-02-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2019-03-27	26N	No opposition filed	Effective date: 20190121
2019-03-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180707 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418
2019-04-17	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2019-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180707
2019-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418
2020-05-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20050707
2020-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418
2020-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180818
2023-07-12	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230529
2024-08-01	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PT Payment date: 20240625 Year of fee payment: 20
2024-08-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: TR Payment date: 20240620 Year of fee payment: 20
2024-09-03	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20240726 Year of fee payment: 20
2024-10-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20240729 Year of fee payment: 20
2024-10-11	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GR Payment date: 20240726 Year of fee payment: 20
2024-10-14	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20240729 Year of fee payment: 20
2024-10-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BE Payment date: 20240729 Year of fee payment: 20
2024-10-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20240725 Year of fee payment: 20
2024-10-21	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20240801 Year of fee payment: 20 Ref country code: CH Payment date: 20240801 Year of fee payment: 20
2024-10-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20240719 Year of fee payment: 20
2025-07-07	REG	Reference to a national code	Ref country code: DE Ref legal event code: R071 Ref document number: 602005053856 Country of ref document: DE
2025-07-09	REG	Reference to a national code	Ref country code: NL Ref legal event code: MK Effective date: 20250706
2025-07-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2025-07-30	REG	Reference to a national code	Ref country code: GB Ref legal event code: PE20 Expiry date: 20250706
2025-08-28	REG	Reference to a national code	Ref country code: BE Ref legal event code: MK Effective date: 20250707
2025-10-09	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20250715